Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis

Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial

(2015) Alexandra Quittner et al.   Health and Quality of Life Outcomes

Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study

(2012) Judy M. Bradley et al.   EUROPEAN RESPIRATORY JOURNAL

Understanding the natural progression in %FEV1decline in patients with cystic fibrosis: a longitudinal study

(2012) David Taylor-Robinson et al.   THORAX

Resource Use, Costs, and Utility Estimates for Patients with Cystic Fibrosis with Mild Impairment in Lung Function: Analysis of Data Collected Alongside a 48-Week Multicenter Clinical Trial

(2012) Esi Morgan DeWitt et al.   VALUE IN HEALTH

‘Down the rabbit hole’: enhancing the transition process for youth with cystic fibrosis and congenital heart disease by re-imagining the future and time

(2011) F. J. Moola et al.   CHILD CARE HEALTH AND DEVELOPMENT

A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation

(2011) Bonnie W. Ramsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis

(2011) K. de Boer et al.   THORAX

Development of the EQ-5D-Y: a child-friendly version of the EQ-5D

(2010) Nora Wille et al.   QUALITY OF LIFE RESEARCH

Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany

(2009) Daniela Eidt-Koch et al.   BMC Pediatrics